Clinical Trials Logo

Carboplatin Adverse Reaction clinical trials

View clinical trials related to Carboplatin Adverse Reaction.

Filter by:
  • None
  • Page 1

NCT ID: NCT01781988 Completed - Lung Cancer Clinical Trials

Personalized Therapy in Non-small Cell Lung Cancer

PTINCLC
Start date: June 2009
Phase: Phase 2
Study type: Interventional

Excision repair cross complementing 1 (ERCC1) ribonucleotide reductase M1 (RRM1) and thymidylate synthase(TS) are molecular determinants that predict sensitivity or resistance to platinum agents 、 gemcitabine and pemetrexed respectively. Tailored therapy using these molecular determinants suggested patient benefit in a previously reported phase 2 trial. Here, we designed a study for an individual patient analysis of prospectively accrued patients who were treated with the "personalized therapy" approach versus other standard approaches.